logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

The U.S. FDA Approved Oyster Point Pharma Inc Product TYRVAYA™ to Treat Dry Eye Disease

Oyster Point Pharma, Inc.  The U.S. Food and Drug Administration ( FDA ) has approved the Oyster Point Pharma Inc ( OYST ) product TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg for the treatment of signs and symptoms of dry eye disease. TYRVAYA™...

Read More

October 18, 2021

0

Reata Pharmaceuticals Announces Presentations Highlighting Clinical Data for Bardoxolone and Disease Education Data on Alport syndrome

Reata Pharmaceuticals Announcements Reata Pharmaceuticals ( RETA ) announced that the abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) and disease education data on Alport syndrome will be presented at the American Society of Nephrology Kidney Week 2021 being held...

Read More

October 21, 2021

0

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.  

AbbVie Inc UBRELVY Results Published in The Lancet AbbVie Inc ( ABBV ) announced detailed results  published in The Lancet  evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome...

Read More

November 17, 2023

0

Gilead Sciences and Merck Initiate Phase 2 Study Evaluating Lenacapavir and Islatravir for HIV-1

Gilead Sciences and Merck Collaboration to Develop Long-Acting HIV Treatment  Gilead Sciences ( GILD ) and Merck ( MRK ) announced the start of a Phase 2 clinical study evaluating an investigational, once-weekly oral combination treatment regimen of islatravir and...

Read More

October 26, 2021

0

No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences Lead Drug Candidate

Cassava Science: Journal of Neuroscience Review Shows No Evidence of Data Manipulation Cassava Sciences ( SAVA ) has been informed by the  Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012...

Read More

November 4, 2021

0

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ASH

Intellia Therapeutics to Present at ASH Intellia Therapeutics ( NTLA ) announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology ( ASH ) Annual Meeting and Exposition taking place...

Read More

November 6, 2021

0

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of Duchenne Muscular Dystrophy

Italfarmaco in the NEWS  From Milan, Italy: Today, Italfarmaco announced that the U.S. Food and Drug Administration ( FDA ) has approved Duvyzat™ (givinostat) - a novel histone deacetylase ( HDAC ) inhibitor, for the treatment of patients 6 years or...

Read More

March 22, 2024

0

Takeda Pharmaceutical Product LIVTENCITY Granted Approval by the FDA

Takeda Pharmaceutical Granted FDA Approval for LIVTENCITY for Post-Transplant Cytomegalovirus On November 23, 2021 Takeda Pharmaceutical Co Ltd ( TAK ) announced that the U.S. FDA has approved LIVTENCITY™ (maribavir) for adults and pediatric patients (12 years of age or...

Read More

November 25, 2021

0

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics CEO Letter to Shareholders Cognition Therapeutics ( CGTX ) today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024....

Read More

January 4, 2024

0

Sanofi to Acquire Inhibrx, Inc.

Sanofi to Acquire Inhibrx Inc Paris, January 23, 2024, Sanofi ( SNY ) and Inhibrx, Inc. ( INBX ) entered into a definitive agreement under which Sanofi agreed to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx...

Read More

January 23, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 109
  • 110
  • 111
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy